{
  "id": 1767517625933,
  "title": "Migraine: A Comprehensive Clinical Guide",
  "summary": "Migraine is a common recurrent headache disorder ranked as the third most prevalent disorder and seventh highest cause of disability worldwide. This visual guide covers clinical features, diagnostic criteria for aura and retinal variants, and evidence-based management strategies.",
  "date": "2026-01-04T09:07:05.933Z",
  "data": {
    "title": "Migraine: A Comprehensive Clinical Guide",
    "summary": "Migraine is a common recurrent headache disorder ranked as the third most prevalent disorder and seventh highest cause of disability worldwide. This visual guide covers clinical features, diagnostic criteria for aura and retinal variants, and evidence-based management strategies.",
    "summary_illustration": "<svg viewBox='0 0 100 100' xmlns='http://www.w3.org/2000/svg'><circle cx='50' cy='50' r='45' fill='none' stroke='hsl(215, 90%, 45%)' stroke-width='2'/><path d='M30 50 Q 50 15 70 50 Q 50 85 30 50' fill='none' stroke='hsl(215, 90%, 45%)' stroke-width='2'/><path d='M40 50 L 45 40 L 55 60 L 60 50' fill='none' stroke='hsl(215, 90%, 45%)' stroke-width='3' stroke-linecap='round' stroke-linejoin='round'/><path d='M20 20 L 25 25 M 75 25 L 80 20 M 20 80 L 25 75 M 75 75 L 80 80' stroke='hsl(215, 90%, 45%)' stroke-width='2' stroke-linecap='round'/></svg>",
    "sections": [
      {
        "title": "Global Burden of Disease (2010 Survey)",
        "icon": "analytics",
        "type": "chart",
        "layout": "half_width",
        "color_theme": "blue",
        "content": {
          "type": "bar",
          "data": [
            {
              "label": "Prevalence Rank (World)",
              "value": 97
            },
            {
              "label": "Disability Cause Rank",
              "value": 93
            }
          ]
        }
      },
      {
        "title": "Migraine Phases & Symptoms",
        "icon": "history",
        "type": "mindmap",
        "layout": "half_width",
        "color_theme": "purple",
        "content": {
          "center": "Migraine Cycle",
          "branches": [
            "Premonitory Phase: Occurs hours or days before the headache.",
            "Headache Resolution Phase.",
            "Symptoms: Hyperactivity, hypoactivity, depression, food cravings, repetitive yawning, fatigue, neck stiffness and/or pain."
          ]
        }
      },
      {
        "title": "Clinical Features: Migraine With and Without Aura",
        "icon": "clinical_notes",
        "type": "key_point",
        "layout": "full_width",
        "color_theme": "blue",
        "content": [
          "Headache is typically unilateral, pulsating in quality, and moderate or severe in intensity.",
          "It can be aggravated by routine physical activity.",
          "Associated with nausea and/or photophobia and phonophobia (see Box 16.7).",
          "Attacks last between 4 and 72h and can occur with or without aura."
        ]
      },
      {
        "title": "Aura Types and Prevalence",
        "icon": "visibility",
        "type": "chart",
        "layout": "half_width",
        "color_theme": "yellow",
        "content": {
          "type": "bar",
          "data": [
            {
              "label": "Visual (99%)",
              "value": 99
            },
            {
              "label": "Somatosensory (40%)",
              "value": 40
            },
            {
              "label": "Speech/Dysphasia (20%)",
              "value": 20
            },
            {
              "label": "Motor/Hemiparesis (18%)",
              "value": 18
            }
          ]
        }
      },
      {
        "title": "Visual Aura Phenomena Details",
        "icon": "lens_blur",
        "type": "plain_text",
        "layout": "half_width",
        "color_theme": "yellow",
        "content": "Typically starts paracentrally and expands temporally; the advancing edge forms a positive scotoma (flickering/shimmering/zigzag/multicoloured lights), whereas the trailing edge is negatively scotomatous; other visual phenomena include foggy vision, ‘heatwaves’, tunnel vision, and complete loss of vision. Somatosensory aura involves hemisensory paraesthesiae/anaesthesia."
      },
      {
        "title": "Chronic & Retinal Migraine Definitions",
        "icon": "timer",
        "type": "key_point",
        "layout": "full_width",
        "color_theme": "purple",
        "content": [
          "Chronic Migraine: Headaches occur on 15 or more days per month for >3mo, which, on at least 8d/mo, have features of migraine.",
          "Retinal Migraine: This is extremely rare. Repeated attacks of monocular visual disturbance, such as scintillations, scotomas, or blindness, associated with migraine headache (See Box 16.8)."
        ]
      },
      {
        "title": "Box 16.7 Diagnostic Criteria for Migraine with Aura",
        "icon": "rule",
        "type": "table",
        "layout": "full_width",
        "color_theme": "green",
        "content": {
          "headers": [
            "General Characteristics",
            "Criteria (i) and (ii)"
          ],
          "rows": [
            [
              "Aura consists of visual and/or sensory and/or speech/language symptoms, but no motor weakness.",
              "Characterized by gradual development, duration of each symptom ≤1h, mix of positive/negative features, and complete reversibility."
            ],
            [
              "(i) Symptom Reversibility",
              "Aura symptoms (visual, sensory, speech) each fully reversible; NO motor, brainstem, or retinal symptoms."
            ],
            [
              "(ii) Clinical Characteristics (At least two of four)",
              "1. At least one aura symptom spreads gradually over ≥5min, and/or ≥2 symptoms occur in succession. 2. Each symptom lasts 5–60min. 3. At least one symptom is unilateral. 4. Aura accompanied/followed within 60min by headache."
            ]
          ]
        }
      },
      {
        "title": "Box 16.8 Diagnostic Criteria of Retinal Migraine (IHS)",
        "icon": "eye_tracking",
        "type": "key_point",
        "layout": "full_width",
        "color_theme": "green",
        "content": [
          "(A) At least two attacks fulfilling criteria (B) and (C).",
          "(B) Aura consisting of fully reversible monocular positive and/or negative visual phenomena (e.g. scintillations, scotomata, or blindness) confirmed during an attack by clinical visual field examination or patient's drawing (made after clear instruction) of a monocular field defect.",
          "(C) At least two of the following: Aura spreads gradually over ≥5min; Aura symptoms last 5–60min; Aura is accompanied, or followed within 60min, by headache.",
          "(D) Not better accounted for by another ICHD-3 diagnosis, and other causes of amaurosis fugax have been excluded."
        ]
      },
      {
        "title": "Investigations & Red Flags",
        "icon": "search",
        "type": "red_flag",
        "layout": "full_width",
        "color_theme": "red",
        "content": [
          "Diagnosis is clinical with a typical history in the presence of a normal neurological examination.",
          "Atypical feature: Age >55y",
          "Atypical feature: Occipitobasal headache",
          "Atypical feature: Persistent neurological deficits",
          "Required assessment for atypical features: Neuroimaging, carotid Doppler scan, ECG, echocardiography, and vasculitis screen."
        ]
      },
      {
        "title": "Management Strategies",
        "icon": "medical_services",
        "type": "process",
        "layout": "full_width",
        "color_theme": "blue",
        "content": [
          "Step 1: Prophylactic Lifestyle Advice: Limit caffeine (Box 16.9), ensure regular meals, adequate hydration, sleep hygiene, and stress management.",
          "Step 2: Therapeutic Acute Care: Relax in a dark, quiet room. Aspirin or NSAIDs for mild attacks.",
          "Step 3: Acute Triptan Therapy: May be used in combination with NSAID, paracetamol, or prokinetic antiemetics (Limit to 2d/wk or max 10d/mo).",
          "Step 4: Preventative Therapy (e.g., topiramate or propranolol): For chronic migraine if >8 disabling attacks/mo (Max efficacy takes 3-4mo)."
        ]
      },
      {
        "title": "Box 16.9 Medication Overuse Headache",
        "icon": "warning",
        "type": "remember",
        "layout": "half_width",
        "color_theme": "red",
        "content": {
          "mnemonic": "MOH Criteria",
          "explanation": "2° headache on ≥15d/mo due to overuse of acute meds (on ≥10 or 15d/mo) for >3mo. Culprits: paracetamol, codeine, triptans, caffeine. Withdrawal lasts up to 3wk."
        }
      },
      {
        "title": "References & Source Material",
        "icon": "menu_book",
        "type": "plain_text",
        "layout": "half_width",
        "color_theme": "blue",
        "content": "24. ICHD-3 beta. Cephalalgia 2013;33:629–808. 25. NICE Clinical guideline [CG150] 2015. 26. Acute therapy limit 10d/mo. 27. Preventative efficacy period 3-4mo. Adapted with permission from SAGE."
      }
    ]
  },
  "chapterId": "neuro",
  "seqId": 84
}